Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement

Neuroscience Letters

Volumn 479, Issue 1, 2010, Pages 13-17

  Lim, Jung Geun ^a   Lee, Jang Jun ^a   Park, Sung Hee ^a   Park, Jae Hyung ^a   Kim, Sun Joo ^a   Cho, Ho Chan ^a   Baek, Won Ki ^a   Kim, Dae Kwang ^a   Song, Dae Kyu ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Epac; GLP 1; Glucokinase; Glucosamine; Glucose uptake; Motor neuron

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE INHIBITOR; ANTIPORTER; EXCHANGE PROTEIN DIRECTLY ACTIVATED BY CYCLIC AMP; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOKINASE; GLUCOSAMINE; GLUCOSE; UNCLASSIFIED DRUG; AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; EPAC PROTEIN, MOUSE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; MOTONEURON; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; ENDOPLASMIC RETICULUM; ENZYMOLOGY; HYBRID CELL; METABOLISM; MOUSE; PHYSIOLOGICAL STRESS; PHYSIOLOGY; TIME; TOXICITY; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM; GLUCAGON-LIKE PEPTIDE 1; GLUCOKINASE; GLUCOSAMINE; GLUCOSE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HYBRID CELLS; MICE; MOTOR NEURONS; PERIPHERAL NERVOUS SYSTEM AGENTS; STRESS, PHYSIOLOGICAL; TIME FACTORS;

EID: 77953726744     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.05.017     Document Type: Article

References (30)

1. Adhihetty P.J., Beal M.F. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromol. Med. 2008, 10:275-290.
2. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat. Rev. Drug Discov. 2009, 8:369-385.
3. Balkan B., Dunning B.E. Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats. Diabetes 1994, 43:1173-1179.
4. Biessels G.J., Bravenboer B., Gispen W.H. Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface. Eur. J. Pharmacol. 2004, 490:1-4.
5. Browne S.E., Yang L., DiMauro J.P., Fuller S.W., Licata S.C., Beal M.F. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol. Dis. 2006, 22:599-610.
6. Buteau J. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab. 2008, 34(Suppl. 2):S73-S77.
7. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 2007, 113:546-593.
8. Eggett C.J., Crosier S., Manning P., Cookson M.R., Menzies F.M., McNeil C.J., Shaw P.J. Development and characterisation of a glutamate-sensitive motor neuron cell line. J. Neurochem. 2000, 74:1895-1902.
9. Hanson M.G., Shen S., Wiemelt A.P., McMorris F.A., Barres B.A. Cyclic AMP elevation is sufficient to promote the survival of spinal motor neurons in vitro. J. Neurosci. 1998, 18:7361-7371.
10. C. Holscher, L. Li, New roles for insulin-like hormones in neuronal signaling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol. Aging, in press.
11. Holz G.G., Chepurny O.G., Schwede F. Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors. Cell. Signal. 2008, 20:10-20.
12. Holz G.G., Kang G., Harbeck M., Roe M.W., Chepurny O.G. Cell physiology of cAMP sensor Epac. J. Physiol. 2006, 577:5-15.
13. Kamata K., Mitsuya M., Nishimura T., Eiki J., Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 2004, 12:429-438.
14. Kanazawa I. How do neurons die in neurodegenerative diseases?. Trends Mol. Med. 2001, 7:339-344.
15. Kaneto H., Xu G., Song K.H., Suzuma K., Bonner-Weir S., Sharma A., Weir G.C. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J. Biol. Chem. 2001, 276:31099-31104.
16. Kashima Y., Miki T., Shibasaki T., Ozaki N., Miyazaki M., Yano H., Seino S. Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. J. Biol. Chem. 2001, 276:46046-46053.
17. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 2008, 60:470-512.
18. Kwon G., Marshall C.A., Pappan K.L., Remedi M.S., McDaniel M.L. Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes 2004, 53(Suppl. 3):S225-S232.
19. Li Y, Perry T., Kindy M.S., Harvey B.K., Tweedie D., Holloway H.W., Powers K., Shen H., Egan J.M., Sambamurti K., Brossi A., Lahiri D.K., Mattson M.P., Hoffer B.J., Wang Y., Greig N.H. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:1285-1290.
20. + currents by Exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J. Biol. Chem. 2003, 278:52446-52453.
21. Martin B., Lopez de Maturana R., Brenneman R., Walent T., Mattson M.P., Maudsley S. Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromol. Med. 2005, 7:3-36.
22. Matthews J.A., Belof J.L., Acevedo-Duncan M., Potter R.L. Glucosamine-induced increase in Akt phosphorylation corresponds to increased endoplasmic reticulum stress in astroglial cells. Mol. Cell. Biochem. 2007, 298:109-123.
23. McEwen B.S., Reagan L.P. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur. J. Pharmacol. 2004, 490:13-24.
24. Pardridge W.M. Brain metabolism: a perspective from the blood-brain barrier. Physiol. Rev. 1983, 63:1481-1535.
25. Perry T.A., Greig N.H. A new Alzheimer's disease interventive strategy: GLP-1. Curr. Drug Targets 2004, 5:565-571.
26. Perry T.A., Greig N.H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2005, 2:377-385.
27. Rizzardini M., Lupi M., Bernasconi S., Mangolini A., Cantoni A.L. Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid. J. Neurol. Sci. 2003, 207:51-58.
28. Roscioni S.S., Elzinga C.R., Schmidt M. Epac: effectors and biological functions. Naunyn-Schmiedebergs Arch. Pharmacol. 2008, 377:345-357.
29. Turner B.J., Atkin J.D. ER stress and UPR in familial amyotrophic lateral sclerosis. Curr. Mol. Med. 2006, 6:79-86.
30. Uldry M., Ibberson M., Hosokawa M., Thorens B. GLUT2 is a high affinity glucosamine transporter. FEBS Lett. 2002, 524:199-203.